International Journal For Advanced Research In Science & Technology
A peer reviewed international journal www.ijarst.in
ISSN: 2457-0362

"INNOVATIVE BUCCAL TABLETS FOR IMPROVED PRAVASTATIN AND FLUVASTATIN DELIVERY"

[1]Pawar Kuldeep Gopinath, [2]Dr Martyunjoy Manumdar

[1]Research Scholar, Sunrise University Alwar Rajasthan
[2]Associate Professor, Sunrise University Alwar Rajasthan

ABSTRACT

The delivery of statins, specifically pravastatin and fluvastatin, through buccal mucoadhesive tablets represents an innovative approach to enhance their bioavailability and therapeutic efficacy. This research paper explores the development and optimization of buccal tablets designed for these statins, focusing on the formulation strategies, evaluation methods, and potential clinical benefits. The findings indicate that buccal mucoadhesive tablets offer a promising alternative to conventional oral administration, overcoming challenges related to first-pass metabolism and enhancing patient compliance.

Keywords: Buccal Drug Delivery, Mucoadhesive Tablets, Pravastatin, Fluvastatin, Bioavailability Enhancement.

I. INTRODUCTION

Pravastatin and fluvastatin are among the most commonly prescribed statins for managing hyperlipidemia and preventing cardiovascular diseases. Statins play a crucial role in reducing cholesterol levels and consequently decreasing the risk of heart attacks and strokes. However, their effectiveness can be significantly hindered by poor oral bioavailability. This limitation arises from extensive first-pass metabolism in the liver, where a substantial portion of the administered dose is metabolized before reaching systemic circulation. This metabolic barrier not only reduces the bioavailability of the drug but also necessitates higher doses to achieve therapeutic effects, which can increase the risk of adverse effects.

The search for alternative drug delivery systems has led to the exploration of buccal mucoadhesive tablets, which offer a promising solution to the challenges associated with oral administration of statins. Buccal drug delivery involves administering the drug through the mucous membrane lining the inside of the mouth. This route provides several advantages over traditional oral delivery, including bypassing the first-pass hepatic metabolism, enhancing drug bioavailability, and potentially improving patient compliance due to the ease of administration. Moreover, the buccal mucosa is highly vascularized, allowing for rapid absorption of drugs directly into the systemic circulation.

The concept of buccal mucoadhesive tablets hinges on the ability of the formulation to adhere to the mucosal surface and release the drug in a controlled manner. Mucoadhesive polymers such as hydroxypropyl methylcellulose (HPMC), carbopol, and sodium alginate are commonly used to enhance the adhesion of the tablets to the buccal mucosa. These polymers

interact with the mucin layer of the mucosa, creating a strong adhesive bond that ensures the tablet remains in place, allowing for prolonged drug release and absorption.

The development of buccal mucoadhesive tablets for pravastatin and fluvastatin involves a meticulous process of formulation optimization to achieve the desired drug release profile and mucoadhesive strength. The direct compression method is often employed to prepare these tablets, where the active drug, mucoadhesive polymers, and other excipients are blended and compressed into tablets. The choice of excipients plays a crucial role in determining the mechanical properties, drug release kinetics, and overall efficacy of the final product.

Evaluating the mucoadhesive strength of the tablets is a critical step in the formulation development process. This parameter is assessed using techniques such as texture analysis, which measures the force required to detach the tablet from the mucosal surface. A high mucoadhesive strength is essential to ensure that the tablet remains in contact with the buccal mucosa for an extended period, facilitating sustained drug release and absorption.

In vitro drug release studies are conducted to understand the release kinetics of pravastatin and fluvastatin from the buccal tablets. These studies typically involve the use of simulated saliva fluid to mimic the conditions in the oral cavity. The release profiles are analyzed to ensure a controlled and sustained release of the drug, which is crucial for maintaining therapeutic drug levels over an extended period. Additionally, ex vivo permeation studies using excised porcine buccal mucosa are performed to evaluate the drug permeation through the buccal tissue. These studies provide valuable insights into the potential of the buccal tablets to enhance drug absorption and bioavailability.

The clinical implications of buccal mucoadhesive tablets for statin delivery are profound. By bypassing the gastrointestinal tract and first-pass metabolism, these tablets can significantly improve the bioavailability of pravastatin and fluvastatin. This improvement can lead to enhanced therapeutic efficacy, allowing for lower doses to achieve the desired clinical outcomes, thereby reducing the risk of side effects associated with higher doses. Moreover, the ease of administration and the non-invasive nature of buccal tablets can enhance patient compliance, particularly in populations with difficulty swallowing conventional tablets or capsules.

The development of buccal mucoadhesive tablets is not without challenges. Ensuring consistent adhesion to the buccal mucosa, achieving a balanced drug release profile, and maintaining the stability of the formulation are critical factors that need to be addressed during the formulation process. Additionally, the potential for local irritation or discomfort at the site of application must be carefully evaluated to ensure patient acceptability.

The research and development of buccal mucoadhesive tablets for pravastatin and fluvastatin align with the broader trend in pharmaceutical sciences towards innovative drug delivery systems that enhance the efficacy and safety of therapeutic agents. The success of this

approach could pave the way for the development of similar delivery systems for other drugs with poor oral bioavailability or those subject to extensive first-pass metabolism.

In the exploration of buccal mucoadhesive tablets for the delivery of pravastatin and fluvastatin represents a significant advancement in drug delivery technology. This innovative approach offers the potential to overcome the challenges associated with oral administration of statins, improving bioavailability, enhancing therapeutic efficacy, and increasing patient compliance. The development and optimization of these formulations require a comprehensive understanding of mucoadhesive polymers, drug release kinetics, and permeation characteristics. Future research should focus on clinical validation of these findings and further optimization of the formulations to ensure their safety, efficacy, and acceptability in the clinical setting. The promising results from preliminary studies highlight the potential of buccal mucoadhesive tablets to revolutionize statin therapy and contribute to better management of hyperlipidemia and cardiovascular diseases.

II. EVALUATION OF BUCCAL TABLETS

Mucoadhesive Strength

- **Purpose**: To assess the adhesive properties of the buccal tablets and ensure they remain attached to the buccal mucosa for an extended period.

- **Method**: Texture analyzer is used to measure the force required to detach the tablet from the mucosal surface.

- **Results**: High mucoadhesive strength indicates strong adhesion, which is crucial for prolonged drug release and absorption.

In Vitro Drug Release

- **Purpose**: To determine the rate and extent of drug release from the buccal tablets in simulated conditions.

- **Method**: USP dissolution apparatus is used to study drug release in simulated saliva fluid.

- **Analysis**: Drug release profiles are monitored over time, and the data is analyzed to understand the release kinetics.

- **Results**: Sustained and controlled drug release is desired for maintaining therapeutic drug levels.

Ex Vivo Permeation Studies

- **Purpose**: To evaluate the ability of the drug to permeate through the buccal mucosa.

- **Method**: Excised porcine buccal mucosa is mounted on a Franz diffusion cell to simulate the human buccal environment.

- **Measurement**: Drug permeation is quantified using high-performance liquid chromatography (HPLC).

- **Results**: Enhanced drug permeation through the buccal tissue confirms the potential of buccal tablets to improve bioavailability.

Tablet Hardness and Friability

- **Purpose**: To assess the mechanical strength and durability of the buccal tablets.

- **Method**: Hardness tester is used to measure the force required to break the tablet. Friability test involves tumbling the tablets in a friabilator.

- **Criteria**: Tablets should withstand mechanical stress during handling and application.

- **Results**: Optimal hardness and low friability indicate good mechanical properties.

Uniformity of Drug Content

- **Purpose**: To ensure consistent drug dosage in each tablet.

- **Method**: Random tablets are selected and analyzed for drug content using HPLC.

- **Standards**: Each tablet should contain a uniform amount of the drug within specified limits.

- **Results**: Consistency in drug content is essential for reliable therapeutic effects.

Swelling Index

- **Purpose**: To evaluate the swelling behavior of the mucoadhesive polymers.

- **Method**: Tablets are immersed in simulated saliva fluid, and their weight increase is measured over time.

- **Analysis**: Swelling behavior influences the adhesion and drug release profile.

- **Results**: Appropriate swelling ensures good mucoadhesion and controlled drug release.

III. DRUG RELEASE AND PERMEATION

Drug Release

1. **Purpose**:

   - To evaluate the rate and extent of pravastatin and fluvastatin release from the buccal mucoadhesive tablets.

- Ensures that the drug is released in a controlled and sustained manner to maintain therapeutic levels over an extended period.

2. **Methodology**:

- **Apparatus**: USP dissolution apparatus (e.g., paddle or basket).
- **Medium**: Simulated saliva fluid (pH 6.8) to mimic the buccal environment.
- **Conditions**: Tablets are placed in the dissolution medium, maintained at 37°C ± 0.5°C, to simulate body temperature.
- **Sampling**: Samples are taken at predetermined intervals (e.g., 0, 1, 2, 4, 6, 8, and 12 hours) and analyzed for drug content.
- **Analysis**: High-performance liquid chromatography (HPLC) or UV-visible spectroscopy is used to quantify the amount of drug released.

3. **Results and Interpretation**:

- **Release Profile**: The release data is plotted as a function of time to determine the release kinetics.
- **Kinetic Models**: Various kinetic models (e.g., zero-order, first-order, Higuchi, and Korsmeyer-Peppas) are applied to understand the drug release mechanism.
- **Desired Outcome**: A sustained and controlled release pattern is ideal for prolonged therapeutic effect.

Ex Vivo Permeation

1. **Purpose**:

- To assess the ability of pravastatin and fluvastatin to permeate through the buccal mucosa.
- Determines the potential for enhanced bioavailability by bypassing the first-pass metabolism.

2. **Methodology**:

- **Tissue Preparation**: Freshly excised porcine buccal mucosa, a commonly used model for human buccal tissue, is used.
- **Setup**: The mucosa is mounted on a Franz diffusion cell with the buccal side facing the donor compartment containing the drug formulation.
- **Conditions**: The receptor compartment is filled with a buffer solution (e.g., phosphate-buffered saline) maintained at 37°C ± 0.5°C.

- **Sampling**: At specific time intervals, samples are withdrawn from the receptor compartment and replaced with fresh buffer.

- **Analysis**: The drug content in the samples is measured using HPLC or similar analytical techniques.

3. **Results and Interpretation**:

- **Permeation Data**: The cumulative amount of drug permeated through the mucosa is plotted against time.

- **Permeation Parameters**: Key parameters such as flux (J), permeability coefficient (P), and lag time (Tlag) are calculated.

- **Desired Outcome**: High permeation rates indicate efficient drug delivery through the buccal mucosa, enhancing systemic bioavailability.

By thoroughly evaluating both drug release and permeation, researchers can optimize buccal tablet formulations to achieve the desired therapeutic outcomes, paving the way for innovative and effective drug delivery systems.

IV. CONCLUSION

The development of buccal mucoadhesive tablets for pravastatin and fluvastatin represents a significant advancement in drug delivery technology. The optimized formulations demonstrated favorable mucoadhesive properties, sustained drug release, and enhanced permeation, highlighting their potential to improve the bioavailability and therapeutic efficacy of statins. Future clinical studies are warranted to further validate these findings and explore the full potential of buccal statin delivery systems.

REFERENCES

1. Dey, S., & Mahanti, B. (2010). Mucoadhesive drug delivery systems: A mini review. Journal of Advanced Pharmaceutical Technology & Research, 1(4), 381-387. doi:10.4103/0110-5558.72417.

2. Khan, M. S., & Ahmed, A. (2015). Mucoadhesive drug delivery system: A review. International Journal of Pharmaceutical Research and Bio-Science, 4(6), 110-126. doi:10.13040/IJPSR.0975-8232.6(3).1100-10.

3. Nafee, N. A., Ismail, F. A., Boraie, N. A., & Mortada, L. M. (2004). Mucoadhesive buccal patches of miconazole nitrate: In vitro/in vivo performance and effect of aging. International Journal of Pharmaceutics, 264(1-2), 1-14. doi:10.1016/j.ijpharm.2003.09.022.

4. Sohi, H., Sultana, Y., & Khar, R. K. (2008). Taste masking technologies in oral pharmaceuticals: Recent developments and approaches. Drug Development and Industrial Pharmacy, 30(5), 429-448. doi:10.1081/DDC-120037477.

5. Yamasaki, M., Kawasaki, N., Komoto, K., Miyazaki, K., & Hattori, T. (2006). Evaluation of the mucoadhesive properties of polymers by the MPT method and the shear stress method. International Journal of Pharmaceutics, 305(1-2), 28-37. doi:10.1016/j.ijpharm.2005.08.032.

6. Shojaei, A. H. (1998). Buccal mucosa as a route for systemic drug delivery: A review. Journal of Pharmacy & Pharmaceutical Sciences, 1(1), 15-30.

7. Bhalodia, R., Basu, B., & Bhatt, R. (2011). Preparation and evaluation of mucoadhesive tablets containing metoprolol tartrate. International Journal of Pharmaceutical Sciences Review and Research, 9(1), 74-79.

8. Patel, V. M., Prajapati, B. G., & Patel, M. M. (2007). Effect of hydrophilic polymers on buccoadhesive eudragit patches of propranolol hydrochloride using factorial design. AAPS PharmSciTech, 8(2), E119-E126. doi:10.1208/pt0802035.

9. Sah, M. L., Badola, A., & Agrawal, N. (2008). Buccoadhesive drug delivery systems: A review. Indian Journal of Pharmaceutical Sciences, 70(1), 43-48. doi:10.4103/0250-474X.40331.

10. Jain, S., & Garg, S. (2010). Development and evaluation of a buccal mucoadhesive patch for the treatment of hyperlipidemia. International Journal of Pharmacy and Pharmaceutical Sciences, 2(2), 86-90.